NCT07898813
Daraxonrasib in Resectable PDAC
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Secondary (5)
Arms and interventions
Participants receive oral daraxonrasib once daily at a predetermined dose for 6 weeks before surgery, followed by a surgical planning interval, surgical resection, adjuvant chemotherapy with or without radiation per institutional standard and investigator discretion, and optional adjuvant daraxonrasib after completion of adjuvant therapy.
Participants receive oral daraxonrasib once daily at a predetermined dose for 12 weeks before surgery, followed by a surgical planning interval, surgical resection, adjuvant chemotherapy with or without radiation per institutional standard and investigator discretion, and optional adjuvant daraxonrasib after completion of adjuvant therapy.
Drugs: Daraxonrasib, Adjuvant Chemotherapy
Procedures: Surgical Resection
Radiation: Adjuvant Radiation Therapy
Sites
2 sites in 1 country